Whalesbook
EBITDA and Margin Pressures
The company's Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) fell 60% year-on-year to ₹98.7 crore, leading to a significant drop in EBITDA margin from 27.3% to 15.9%. While gross margins actually improved to 65.4%, and adjusted EBITDA was ₹130 crore, these figures show a more complex financial picture due to specific adjustments and standalone performance, differing from the consolidated results which were impacted by operational costs.
Recovery Expected in FY27
Looking ahead, management expects growth to return in the second half of fiscal year 2027. The first quarter of FY27 is projected to be the weakest for both revenue and EBITDA. The company plans to drive this recovery through ongoing program execution, securing new customers, and better use of its manufacturing capacity.
Strong Pipeline Offers Future Growth
Despite current financial pressures, Cohance Lifesciences highlighted its strong pipeline. The company reported steady inflow of Requests for Proposals (RFPs) for small molecules, Antibody-Drug Conjugates (ADCs), and complex chemistries, maintaining inflows at twice the rate of new opportunities. Focus is now on improving success rates for key late-stage projects.